Alivus Life Sciences Peer Comparison
NSE: GLS | BSE: 543322
₹1,388.70
₹14.50
(1.06%)
As on 23-Sep-2026 10:24IST
Market cap
₹17,335 Cr
Revenue (TTM)
₹2,590 Cr
P/E Ratio
28.7
P/B Ratio
5
Div. Yield
0.4 %
Edit
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
17,335 | 37,563 | 29,118 | 16,115 | 13,491 |
Revenue (₹ Cr) |
2,590 | 9,683 | 2,372 | 1,108 | 676 |
Net Profit (₹ Cr) |
603.02 | 1,018.97 | 497.77 | 270.18 | 183.60 |
Net Margin (%) |
22.63 | 10.47 | 20.72 | 23.29 | 26.06 |
RoE (%) |
19.61 | 21.30 | 28.49 | 14.45 | 22.72 |
Price to Earnings |
28.75 | 37.14 | 58.50 | 58.52 | 73.87 |
Price-To-Book |
4.97 | 7.18 | 14.41 | 7.77 | 14.60 |
Income Statement (₹ Cr)
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,590.40 | 9,683.45 | 2,371.81 | 1,108.39 | 675.61 |
|
Total Income
|
2,664.23 | 9,730.84 | 2,402.61 | 1,159.90 | 704.48 |
|
Total Expenditure
|
1,753.71 | 7,739.53 | 1,608.91 | 720.01 | 442.67 |
|
EBITDA
|
836.69 | 1,943.92 | 762.90 | 388.38 | 232.94 |
|
Depreciation
|
78.88 | 425.10 | 98.11 | 74.78 | 15.56 |
|
EBIT
|
757.81 | 1,518.82 | 664.79 | 313.60 | 217.38 |
|
Interest
|
5.43 | 148.45 | 26.33 | 0.26 | 7.96 |
|
Other Income
|
73.83 | 47.39 | 30.80 | 51.50 | 28.87 |
|
Exceptional Items
|
-25.66 | -27.85 | 0.00 | -3.28 | 0.00 |
|
Profit before Tax
|
800.55 | 1,389.91 | 669.26 | 361.56 | 238.30 |
|
Provision for Tax
|
197.53 | 370.94 | 171.48 | 91.39 | 54.69 |
|
Profit after Tax
|
603.02 | 1,018.97 | 497.77 | 270.18 | 183.60 |
Liabilities (₹ Cr)
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
3,332.13 | 4,950.03 | 1,874.47 | 2,017.06 | 883.34 |
|
Minority Interest
|
0.00 | -7.58 | 0.00 | 2.51 | -0.97 |
|
Non-Current Liabilities
|
142.73 | 723.57 | 345.47 | 50.51 | 74.82 |
|
Current Liabilities
|
508.04 | 3,912.24 | 710.20 | 169.08 | 201.96 |
|
Total Liabilities
|
4,157.10 | 9,514.48 | 2,930.14 | 2,231.79 | 1,174.38 |
Assets (₹ Cr)
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,321.38 | 3,392.16 | 1,290.62 | 957.22 | 477.92 |
|
Current Assets
|
2,649.36 | 5,612.10 | 1,483.13 | 1,250.11 | 623.97 |
|
Total Assets
|
4,157.10 | 9,514.48 | 2,930.14 | 2,231.79 | 1,174.38 |
|
Total Debt*
|
0.00 | 1,204.08 | 196.61 | 0.00 | 148.29 |
|
Net Current Assets
|
2,141.33 | 1,699.86 | 772.93 | 1,081.04 | 422.01 |
|
Contingent Liabilities
|
4.82 | 258.92 | 13.18 | 3.76 | -- |
Cashflow (₹ Cr)
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
565.41 | 943.55 | 346.68 | 266.88 | 69.55 |
|
Cash Flow from Investing Activities
|
-570.15 | -1,193.06 | -423.73 | -142.72 | -330.93 |
|
Cash from Financing Activities
|
-64.34 | 343.43 | 20.98 | -112.88 | 247.29 |
|
Net Cash Inflow / Outflow
|
-69.08 | 93.92 | -56.08 | 11.28 | -14.09 |
Ratios
Profitability Ratios
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
24.61 | 25.25 | 27.50 | 18.04 | 28.50 |
|
ROE (%)
|
19.61 | 21.30 | 28.49 | 14.45 | 22.72 |
|
ROA (%)
|
16.31 | 11.42 | 19.48 | 12.66 | 31.25 |
|
EBIT Margin (%)
|
29.25 | 15.68 | 28.03 | 28.29 | 32.18 |
|
Net Margin (%)
|
22.63 | 10.47 | 20.72 | 23.29 | 26.06 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
7.93 | 18.36 | 78.33 | -6.72 | 23.56 |
|
EBIT Growth (%)
|
19.88 | 30.43 | 303.07 | -26.64 | 12.00 |
|
Net Profit Growth (%)
|
21.66 | 32.39 | 182.61 | -24.38 | 20.07 |
|
EPS Growth (%)
|
25.42 | 36.68 | 277.72 | -21.99 | 50.65 |
|
Book Value Growth (%)
|
18.43 | 11.36 | 22.95 | 11.27 | 79.97 |
Valuation Ratios
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
27.11 | 36.29 | 58.07 | 57.64 | 71.26 |
|
Price / Book Value
|
4.84 | 7.17 | 14.30 | 7.72 | 14.66 |
|
Dividend Yield (%)
|
0.36 | 0.18 | 0.15 | 0.49 | 0.13 |
|
EV/EBITDA
|
19.24 | 19.82 | 37.68 | 40.16 | 58.27 |
|
Market Cap (₹ Cr)
|
11,956.86 | 30,257.56 | 15,412.11 | 10,627.92 | 6,690.53 |
Solvency Ratios
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.05 | 0.09 | 0.00 | 0.04 |
|
Short term debt to equity ratio
|
-- | 0.16 | -- | -- | 0.12 |
|
Current Ratio
|
5.21 | 1.43 | 2.09 | 7.39 | 3.09 |
|
Quick Ratio
|
3.85 | 0.82 | 1.37 | 5.46 | 2.02 |
|
Interest Coverage
|
148.49 | 10.36 | 26.41 | 1,386.30 | 30.94 |
Operating Efficiency Ratios
| Alivus Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Concord Biotech | Sudeep Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
41.42 | 26.46 | 22.82 | 41.52 | 33.68 |
|
Asset Turnover
|
0.70 | 1.09 | 0.93 | 0.52 | 1.15 |
|
Receivable days
|
144.58 | 88.68 | 77.32 | 169.86 | 115.16 |
|
Inventory Days
|
96.67 | 84.11 | 80.83 | 97.92 | 96.15 |
|
Payable days
|
135.45 | 176.65 | 125.94 | 159.68 | 106.08 |
|
Cash Conversion Cycle
|
105.80 | -3.86 | 32.22 | 108.11 | 105.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
